Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 02 04:00PM ET
6.87
Dollar change
-0.42
Percentage change
-5.76
%
Index- P/E134.44 EPS (ttm)0.05 Insider Own8.61% Shs Outstand7.48M Perf Week-5.37%
Market Cap54.03M Forward P/E- EPS next Y-7.81 Insider Trans-0.11% Shs Float3.71M Perf Month-19.74%
Income8.62M PEG- EPS next Q-2.28 Inst Own81.17% Short Float6.47% Perf Quarter-33.94%
Sales75.10M P/S0.72 EPS this Y101.67% Inst Trans23.63% Short Ratio3.12 Perf Half Y-47.56%
Book/sh8.67 P/B0.79 EPS next Y-3037.59% ROA7.23% Short Interest0.24M Perf Year-35.51%
Cash/sh12.87 P/C0.53 EPS next 5Y- ROE24.44% 52W Range6.41 - 19.43 Perf YTD-37.26%
Dividend Est.- P/FCF- EPS past 5Y7.97% ROI9.18% 52W High-64.64% Beta1.40
Dividend TTM- Quick Ratio9.22 Sales past 5Y101.03% Gross Margin92.84% 52W Low7.18% ATR (14)0.46
Dividend Ex-Date- Current Ratio9.22 EPS Y/Y TTM100.37% Oper. Margin-21.58% RSI (14)36.39 Volatility6.37% 6.23%
Employees109 Debt/Eq0.47 Sales Y/Y TTM43.62% Profit Margin11.48% Recom1.50 Target Price35.75
Option/ShortNo / Yes LT Debt/Eq0.45 EPS Q/Q47.63% Payout- Rel Volume0.89 Prev Close7.29
Sales Surprise-89.20% EPS Surprise-5.34% Sales Q/Q-95.61% EarningsNov 04 BMO Avg Volume76.76K Price6.87
SMA20-10.10% SMA50-18.18% SMA200-34.49% Trades Volume68,690 Change-5.76%
Date Action Analyst Rating Change Price Target Change
Apr-30-24Initiated Guggenheim Buy $19
Jun-17-22Initiated BMO Capital Markets Outperform $7
Jun-09-22Downgrade William Blair Outperform → Mkt Perform
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
Nov-21-24 07:01AM
Nov-15-24 07:00AM
Nov-04-24 08:15AM
07:13AM
07:01AM
07:43AM Loading…
Nov-01-24 07:43AM
Oct-29-24 07:01AM
Oct-28-24 07:01AM
Oct-24-24 04:15PM
08:47AM
Oct-21-24 07:01AM
Oct-16-24 07:01AM
Oct-03-24 07:01AM
Sep-30-24 07:01AM
Sep-20-24 07:01AM
09:55AM Loading…
Sep-13-24 09:55AM
Sep-12-24 07:15AM
Sep-11-24 08:50AM
Sep-04-24 07:01AM
Sep-03-24 07:01AM
Aug-28-24 09:55AM
Aug-12-24 04:32AM
Aug-09-24 07:01AM
Aug-01-24 08:25AM
07:22AM
07:15AM
Jul-31-24 07:01AM
Jul-29-24 04:15PM
Jul-08-24 07:01AM
Jul-01-24 07:01AM
07:01AM Loading…
Jun-27-24 07:01AM
Jun-20-24 07:00AM
Jun-05-24 07:01AM
May-30-24 07:00AM
May-29-24 09:55AM
May-17-24 07:00AM
May-13-24 11:53AM
07:22AM
07:08AM
07:00AM
May-08-24 08:15AM
May-07-24 04:30PM
08:30AM
May-03-24 09:33AM
May-01-24 07:05AM
Apr-16-24 04:15PM
Apr-11-24 09:55AM
Apr-02-24 09:55AM
06:48AM
Mar-27-24 11:53AM
08:10AM
07:07AM
06:45AM
Mar-20-24 04:30PM
Mar-19-24 07:00AM
Mar-14-24 08:15AM
Mar-06-24 08:45AM
Mar-01-24 06:30AM
Feb-29-24 04:01PM
09:22AM
Feb-27-24 04:25AM
Feb-20-24 07:00AM
Feb-14-24 07:00AM
Feb-13-24 07:00AM
Feb-12-24 07:00AM
Feb-09-24 07:00AM
Jan-09-24 07:00AM
07:00AM
Dec-13-23 08:20AM
Dec-04-23 07:00AM
Nov-30-23 07:00AM
Nov-28-23 07:00AM
Nov-14-23 08:55AM
Nov-13-23 07:05AM
Nov-10-23 07:00AM
Nov-09-23 07:00AM
Nov-07-23 07:54AM
07:17AM
07:00AM
Nov-01-23 07:00AM
Oct-26-23 07:30AM
Oct-23-23 07:00AM
Oct-12-23 08:00AM
Sep-27-23 07:00AM
Sep-12-23 07:00AM
Sep-06-23 07:00AM
Aug-31-23 07:00AM
Aug-22-23 07:32AM
07:32AM
Aug-18-23 09:35AM
Aug-15-23 07:04PM
Aug-06-23 08:03AM
Aug-04-23 08:35AM
07:23AM
07:15AM
Aug-01-23 05:00PM
Jul-27-23 07:30AM
Jul-13-23 01:03PM
Jun-22-23 07:00AM
Jun-05-23 07:00AM
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly John AlexanderChief Financial OfficerNov 21 '24Buy6.763,00020,28038,073Nov 21 04:30 PM
Scimeca DarioGeneral Counsel and SecretaryNov 02 '24Option Exercise0.001,83608,557Nov 05 07:14 PM
Scimeca DarioGeneral Counsel and SecretaryNov 04 '24Sale8.195884,8167,969Nov 05 07:14 PM
Amoroso MichaelPresident and CEONov 04 '24Sale8.193,01224,66828,537Nov 05 07:14 PM
Scimeca DarioOfficerNov 04 '24Proposed Sale8.195884,816Nov 04 03:51 PM
Amoroso MichaelOfficerNov 04 '24Proposed Sale8.193,01224,669Nov 04 03:49 PM
Scimeca DarioGeneral Counsel and SecretaryJun 07 '24Option Exercise0.0030106,814Jun 11 05:13 PM
Scimeca DarioGeneral Counsel and SecretaryJun 10 '24Sale11.79931,0966,721Jun 11 05:13 PM
SMITH J. JEFFERSONChief Research OfficerJun 10 '24Sale11.795059068,559Jun 11 05:12 PM
Scimeca DarioGeneral Counsel and SecretaryMay 02 '24Sale10.322722,8075,680May 03 06:33 PM
SMITH J. JEFFERSONChief Research OfficerMay 02 '24Sale10.321541,58967,613May 03 06:32 PM
List AlanChief Medical OfficerMay 02 '24Sale10.322902,9934,488May 03 06:30 PM
Amoroso MichaelPresident and CEOMay 02 '24Sale10.321,52615,74813,772May 03 06:29 PM
List AlanChief Medical OfficerApr 30 '24Sale10.032382,3863,796Apr 30 06:34 PM
Amoroso MichaelPresident and CEOJan 22 '24Sale0.36137,39049,460356,433Jan 23 07:17 PM
Scimeca DarioGeneral Counsel and SecretaryJan 22 '24Sale0.3621,2877,663151,028Jan 23 07:15 PM
List AlanChief Medical OfficerJan 22 '24Sale0.3621,5267,74994,982Jan 23 07:13 PM
SMITH J. JEFFERSONChief Research OfficerJan 23 '24Sale0.3728,00010,3601,987,269Jan 23 07:11 PM